Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 28, 2015 9:25 AM ET


Company Overview of Yeda Research and Development Company Ltd.

Company Overview

Yeda Research and Development Company Ltd., a technology transfer company, markets and commercializes intellectual properties that are created in the laboratories of Weizmann Institute of Science. The company identifies and assesses research projects with commercial potential, protects the intellectual property of the institute and its scientists, licenses the institute’s inventions and technologies to industry, and channels funding from industry to research projects. It markets and commercializes intellectual properties that cover a range of natural sciences, including biotechnology, pharmaceuticals, and diagnostics; bioinformatics, proteomics, biomatics, and system biology; medical devices...

Weizman Institue of Science

de Botton Building (Building No. 5)

P.O. Box 95

Rehovot,  76100


Founded in 1959


972 8 947 0617


972 8 947 0739

Key Executives for Yeda Research and Development Company Ltd.

Chief Executive Officer
Chief Financial Officer
Chief Intellectual Property Officer
Chif Business Officer
General Counsel
Compensation as of Fiscal Year 2015.

Yeda Research and Development Company Ltd. Key Developments

Hyperion Therapeutics Enters into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement with Clal Biotechnology Industries Ltd. and Yeda Research and Development Company Ltd

Hyperion Therapeutics, Inc. announced that it has amicably resolved its disputes, and entered into a completion of phase III clinical trial, option and mutual release agreement with Clal Biotechnology Industries Ltd. (CBI) and Yeda Research and Development Company Ltd. (Yeda) regarding DiaPep277, a product candidate developed by Andromeda Biotech Ltd., a company which Hyperion acquired from CBI in June 2014. Hyperion will complete the ongoing DIA-AID 2 phase 3 clinical trial of DiaPep277 to treat new onset Type 1 diabetes and will not take DiaPep277 forward beyond completion of the DIA-AID 2 trial.  Hyperion's estimated budget for completion of the DIA-AID 2 trial remains unchanged at $10.5 million. CBI will have an option to acquire Andromeda, which option expires September 30, 2015. CBI will pay a nonrefundable option payment of $2.5 million at signing, payable in shares of Hyperion stock currently held by CBI. Subject to agreed restrictions, a steering committee consisting of representatives from CBI, Yeda and Hyperion, will oversee and direct the completion of the trial, the analysis of its results, and interactions with regulatory authorities. Hyperion intends to use the option payment to offset any potential increases to the DIA-AID2 trial budget incurred at the steering committee's direction. Any increases to this budget beyond $2.25 million, if incurred at the steering committee's direction, will be reimbursed by CBI. If CBI exercises the option, CBI will pay an option exercise price of $3.5 million, payable in shares of Hyperion stock currently held by CBI. In addition, if the option is exercised, then Andromeda will be obligated to pay Hyperion future contingent payments if and to the extent it or its shareholders receive revenues or certain other proceeds, which are capped at $36.5 million. This amount, together with the option exercise price that Hyperion may receive, approximates the total amount Hyperion will have invested in Andromeda by the option exercise date. If CBI does not exercise the option, the Agreement provides for DiaPep277 intellectual property rights to revert to Yeda. Mutual releases of DiaPep277-related claims were exchanged among Hyperion, Andromeda, CBI, Yeda and Teva Pharmaceutical Industries Ltd.

Rosetta Genomics Announces Collaborative Research and License Agreement with Yeda Research and Development Company Ltd. for Personalized Medicine

Rosetta Genomics Ltd. announced that the company has entered into a collaborative research and license agreement with Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science. The agreement involves collaboration with the Nancy and Stephen Grand Israel National Center for Personalized Medicine to develop novel methods for the preparation of next-generation sequencing libraries for small RNAs. The initial goals of this collaboration are to make this type of sequencing more cost effective as well as to minimize sequence-specific biases. The collaboration also aims at developing computational methods required for data analysis. The potential developed methods could allow more accurate quantification of microRNAs in various biological samples and pathological conditions.

XTL Biopharmaceuticals Signs a Licensing Agreement with Yeda Research and Development Company to Develop hCDR1

XTL Biopharmaceuticals announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1, a peptide developed by Prof. Edna Mozes of the Department of Immunology, The Weizmann Institute of Science, acts as a disease-specific treatment to modify the SLE-related autoimmune process by specific upstream immunomodulation through the generation of regulatory T cells, reducing inflammation and resuming immune balance. More than 40 peer-reviewed papers have been published on hCDR1. Two placebo controlled Phase I trials and a placebo controlled Phase II trial (PRELUDE) were conducted by Teva Pharmaceutical Industries, which had previously in-licensed hCDR1 from Yeda. The Phase I and Phase II studies consisted of over 400 patients, demonstrating that hCDR1 is well tolerated by patients and has a favorable safety profile. The PRELUDE trial did not achieve its primary efficacy endpoint based on the SLEDAI scale, resulting in Teva returning the asset to Yeda. However, the PRELUDE trial showed encouraging results in its secondary clinical endpoint, the BILAG index, and, in fact, the 0.5 mg weekly dose showed a substantial effect. Multiple post-hoc analyses also showed good results for this dose using the BILAG index. Such dose will be the focus of the clinical development plan moving forward. The FDA has since directed that the primary endpoint in future trials for Lupus therapies, including those for hCDR1, should be based on either the BILAG index or the SLE Responder Index (SRI).

Similar Private Companies By Industry

Company Name Region
Reshet TV Middle East/Africa
DC Finance Middle East/Africa
Haaretz Daily Newspaper Ltd. Middle East/Africa
Jasmine Group Middle East/Africa
WebPals LTD. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Yeda Research and Development Company Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at